296 related articles for article (PubMed ID: 32058159)
41. Clinical implications of imprecise sampling time for 10- and 30-min thyrotropin-releasing hormone stimulation tests in horses.
Vorster DM; Wang W; Kemp KL; Bamford NJ; Bertin FR
Equine Vet J; 2024 Mar; 56(2):291-298. PubMed ID: 37649416
[TBL] [Abstract][Full Text] [Related]
42. Influence of season and pituitary pars intermedia dysfunction on hair cortisol concentration in horses.
Banse HE; Getachew F; Levy M; Smits J
Domest Anim Endocrinol; 2020 Jul; 72():106375. PubMed ID: 31431311
[TBL] [Abstract][Full Text] [Related]
43. The effects of sample handling and N-phenylmaleimide on concentration of adrenocorticotrophic hormone in equine plasma.
Rendle DI; Litchfield E; Gough S; Cowling A; Hughes KJ
Equine Vet J; 2015 Sep; 47(5):587-91. PubMed ID: 24980684
[TBL] [Abstract][Full Text] [Related]
44. Impact of blue light therapy on plasma adrenocorticotropic hormone (ACTH) and hypertrichosis in horses with pituitary pars intermedia dysfunction.
Miller AB; Murphy BA; Adams AA
Domest Anim Endocrinol; 2022 Jan; 78():106651. PubMed ID: 34656964
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of basal plasma α-melanocyte-stimulating hormone and adrenocorticotrophic hormone concentrations for the diagnosis of pituitary pars intermedia dysfunction from a population of aged horses.
Mc Gowan TW; Pinchbeck GP; Mc Gowan CM
Equine Vet J; 2013 Jan; 45(1):66-73. PubMed ID: 22563728
[TBL] [Abstract][Full Text] [Related]
46. Prevalence, risk factors and clinical signs predictive for equine pituitary pars intermedia dysfunction in aged horses.
McGowan TW; Pinchbeck GP; McGowan CM
Equine Vet J; 2013 Jan; 45(1):74-9. PubMed ID: 22594955
[TBL] [Abstract][Full Text] [Related]
47. Markers of muscle atrophy and impact of treatment with pergolide in horses with pituitary pars intermedia dysfunction and muscle atrophy.
Banse HE; Whitehead AE; McFarlane D; Chelikani PK
Domest Anim Endocrinol; 2021 Jul; 76():106620. PubMed ID: 33740552
[TBL] [Abstract][Full Text] [Related]
48. Comparison of hair follicle histology between horses with pituitary pars intermedia dysfunction and excessive hair growth and normal aged horses.
Innerå M; Petersen AD; Desjardins DR; Steficek BA; Rosser EJ; Schott HC
Vet Dermatol; 2013 Feb; 24(1):212-7.e46-7. PubMed ID: 23331700
[TBL] [Abstract][Full Text] [Related]
49. Effects of polyphenols including curcuminoids, resveratrol, quercetin, pterostilbene, and hydroxypterostilbene on lymphocyte pro-inflammatory cytokine production of senior horses in vitro.
Siard MH; McMurry KE; Adams AA
Vet Immunol Immunopathol; 2016 May; 173():50-9. PubMed ID: 27090627
[TBL] [Abstract][Full Text] [Related]
50. Diagnostic frequency, response to therapy, and long-term prognosis among horses and ponies with pituitary par intermedia dysfunction, 1993-2004.
Rohrbach BW; Stafford JR; Clermont RS; Reed SM; Schott HC; Andrews FM
J Vet Intern Med; 2012; 26(4):1027-34. PubMed ID: 22524260
[TBL] [Abstract][Full Text] [Related]
51. Influence of feeding and other factors on adrenocorticotropin concentration and thyrotropin-releasing hormone stimulation test in horses and ponies.
Drozdzewska K; Winter J; Barton AK; Merle R; Gehlen H
Equine Vet J; 2024 Mar; 56(2):342-351. PubMed ID: 38010866
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of seasonal influences on adrenocorticotropic hormone response to the thyrotropin-releasing hormone stimulation test and its accuracy for diagnosis of pituitary pars intermedia dysfunction.
Adams AA; Siard-Altman MH; Reedy SE; Barker D; Elzinga S; Sanz MG; Urschel K; Ireland JL
Vet J; 2023; 300-302():106035. PubMed ID: 37802466
[TBL] [Abstract][Full Text] [Related]
53. PITUITARY PARS INTERMEDIA DYSFUNCTION (EQUINE CUSHING'S DISEASE) IN NONDOMESTIC EQUIDS AT MARWELL WILDLIFE: A CASE SERIES. ONE CHAPMAN'S ZEBRA ( EQUUS QUAGGA CHAPMANI) AND FIVE PRZEWALSKI's HORSES ( EQUUS FERUS PRZEWALSKII).
Shotton JCR; Justice WSM; Salguero FJ; Stevens A; Bacci B
J Zoo Wildl Med; 2018 Jun; 49(2):404-411. PubMed ID: 29900762
[TBL] [Abstract][Full Text] [Related]
54. Case series of equine pituitary pars intermedia dysfunction in a tropical climate.
Spelta CW; Axon JE
Aust Vet J; 2012 Nov; 90(11):451-6. PubMed ID: 23106327
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetic and pharmacodynamic properties of pergolide mesylate following long-term administration to horses with pituitary pars intermedia dysfunction.
McFarlane D; Banse H; Knych HK; Maxwell LK
J Vet Pharmacol Ther; 2017 Apr; 40(2):158-164. PubMed ID: 27301465
[TBL] [Abstract][Full Text] [Related]
56. Clinical implications of using adrenocorticotropic hormone diagnostic cutoffs or reference intervals to diagnose pituitary pars intermedia dysfunction in mature horses.
Horn R; Stewart AJ; Jackson KV; Dryburgh EL; Medina-Torres CE; Bertin FR
J Vet Intern Med; 2021 Jan; 35(1):560-570. PubMed ID: 33368633
[TBL] [Abstract][Full Text] [Related]
57. Fecal strongyle egg counts in horses with suspected pre-clinical pituitary pars intermedia dysfunction before and after treatment with pergolide.
Christen G; Gerber V; van der Kolk JH; Frey CF; Fouché N
Vet J; 2018 May; 235():60-62. PubMed ID: 29704940
[TBL] [Abstract][Full Text] [Related]
58. What's New in Old Horses? Postmortem Diagnoses in Mature and Aged Equids.
Miller MA; Moore GE; Bertin FR; Kritchevsky JE
Vet Pathol; 2016 Mar; 53(2):390-8. PubMed ID: 26459516
[TBL] [Abstract][Full Text] [Related]
59. Epidemiology of pituitary pars intermedia dysfunction: A systematic literature review of clinical presentation, disease prevalence and risk factors.
Ireland JL; McGowan CM
Vet J; 2018 May; 235():22-33. PubMed ID: 29704935
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis.
Donaldson MT; Jorgensen AJ; Beech J
J Am Vet Med Assoc; 2004 Apr; 224(7):1123-7. PubMed ID: 15074858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
